Search results
Results from the WOW.Com Content Network
Serious side effects from the hepatitis B vaccine are very uncommon. [13] Pain may occur at the site of injection. [13] It is safe for use during pregnancy or while breastfeeding. [13] It has not been linked to Guillain–Barré syndrome. [13] Hepatitis B vaccines are produced with recombinant DNA techniques and contain immunologic adjuvant. [13]
Hepatitis B infection has been preventable by vaccination since 1982. [4] [12] As of 2022, the hepatitis B vaccine is between 98% and 100% effective in preventing infection. [1] The vaccine is administered in several doses; after an initial dose, two or three more vaccine doses are required at a later time for full effect. [1]
Combined hepatitis A and B vaccine, is used to provide protection against hepatitis A and hepatitis B. [3] [7] It is given by injection into muscle.[8]It is used in areas where hepatitis A and B are endemic, for travelers, people with hepatitis C or chronic liver disease, and those at high risk of sexually transmitted diseases.
DTwP-HepB-Hib vaccine is a 5-in-1 combination vaccine with five individual vaccines conjugated into one. [1] It protects against diphtheria, tetanus, whooping cough, hepatitis B and Haemophilus influenzae type B, [1] which is generally used in middle- and low-income countries, where polio vaccine is given separately.
A hexavalent vaccine, or 6-in-1 vaccine, is a combination vaccine with six individual vaccines conjugated into one, intended to protect people from multiple diseases. [1] [9] The term usually refers to the children's vaccine that protects against diphtheria, tetanus, pertussis, poliomyelitis, haemophilus B, and hepatitis B, [1] [9] which is used in more than 90 countries around the world ...
DTP-HepB vaccine is a combination vaccine whose generic name is diphtheria and tetanus toxoids and whole-cell pertussis and hepatitis B (recombinant) vaccine (adsorbed) or DTP-Hep B. It protects against the infectious diseases diphtheria, tetanus, pertussis, and hepatitis B. [1]
HBIG is indicated as a postexposure prophylaxis for people at risk to develop hepatitis B because they have been recently exposed to body fluids of individuals who have hepatitis B. This includes babies of mothers with hepatitis B, sexual partners, healthcare workers, police and fire workers, and morticians. [6]
Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (European Union) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance.